END2AMR launches to accelerate innovation against drug-resistant bacterial infections
We are proud to announce the launch of END2AMR (European Novel Drug Research to Address Microbial Infections and Drug Resistance) – a new public-private research initiative designed to tackle some of the most difficult-to-treat bacterial infections.
